吉非替尼治疗难治性非小细胞肺癌的疗效  

Gefitinib in treatment of refractory non-small cell lung cancer

作　　者：张燕[1] 陈黎[2] 张品良[2] 徐从高[1] 

机构地区：[1]山东大学齐鲁医院血液学研究室,山东济南250012 [2]山东省肿瘤医院内科,山东济南250117

出　　处：《中国新药与临床杂志》2006年第3期196-199,共4页Chinese Journal of New Drugs and Clinical Remedies

摘　　要：目的:探讨吉非替尼治疗难治性非小细胞肺癌的疗效和不良反应。方法:共入组难治性非小细胞肺癌47例,给吉非替尼250 mg每日1次口服,直至肿瘤进展或病人不能耐受治疗的毒性而中止治疗。至少服药16 wk后评价疗效。结果:全组总有效率34％[(16／47);完全缓解(CR)1例,部分缓解(PR)15例],疾病控制率为83％(39／47;CR 1例,PR 15例,稳定23例)。男性组和女性组的有效率分别为50％和20％(P<0．05), 中位生存期为297 d(118～868 d)。中位疾病进展时间(TTP)173 d(59～693 d)。1 a和6 mo生存率分别为 36％和79％。全组病人症状改善率为89％(42／47)。主要的不良反应是痤疮样皮疹(32％)、腹泻(11％)、恶心呕吐(23％),未发生明显骨髓抑制及间质性肺炎。结论:吉非替尼治疗难治性非小细胞肺癌有一定疗效, 不良反应轻微,可提高病人的生活质量。AIM： To investigate non-small cell lung cancer. METHODS： antitumor effects and toxicities of gefitinib in patients with refractory Forty-seven patients with refractory non-small cell lung cancer were enrolled in the study. Gefitinib was administered orally at 250 mg once a day as a continuous dose until the disease progressed or patients couldn＇t tolerate the toxicities. The course of treatment undertook for at least 16 wk before evaluation. RESULTS： The overall response rate（CR ＋ PR） was 34 % （1 CR, 15 PR ）. The disease control rate（CR＋PR＋SD）was 83 %（1 CR, 15 PR,23 SD）. Median survival time was 297 d （118 - 868 d） and median time to progress was 173 d（59 - 693 d）.One-year and 6 mo survival rates were 36 % and 79 % respectively, with symptom improvement in 89 % of all patients.The main adverse reactions were skin acne-like rash （32 %）, diarrhea（11%）, nausea and vomiting （23 %）,without obvious bone marrow suppression and interstitial lung disease. CONCLUSION： Gefitinib is effective and tolerable for the patients with refractory non-small cell lung cancer. It can remarkably improve patients＇life quality.

关 键 词：癌 非小细胞肺 吉非替尼 药物疗法 

分 类 号：R734.2[医药卫生—肿瘤] R969.4[医药卫生—临床医学]